<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114269</article-id><article-id pub-id-type="publisher-id">ACM-41874</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_17622903.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  间质性肺疾病与血清肿瘤标记物的关系
  Study on the Difference of Tumor Markers in Interstitial Pulmonary Disease, Lung Cancer and Bronchial Asthma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>段</surname><given-names>兴秋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>琨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>云辉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>大理大学临床医学院，云南 大理</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1240</fpage><lpage>1246</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：揭示血清肿瘤标记物(CEA、NSE、CYPRA21-1、CA199、SCC、CA125)与间质性肺疾病之间的关系，肿瘤标记物阳性率及水平在间质性肺疾病(Interstitial pulmonary disease, ILD)、支气管哮喘、肺癌中有无差异；方法：收集2015年5月至2020年12月于云南省第一人民医院确诊为ILD的患者100例，收集同期诊断为支气管哮喘的患者51例，为对照A组，同期病理证实为肺癌的患者53例，为对照B组，测定三组患者血清中CEA、NSE、CYPRA21-1、CA199、SCC、CA125的水平，比较三组中不同血清肿瘤标记物的差异。结果：ILD组血清CEA、NSE、CYPRA21-1、CA125的阳性率与肺癌组无明显差异(P值均 &gt; 0.05)，ILD组、肺癌组中CEA、NSE、CYPRA21-1、CA125的阳性率均高于支气管哮喘组(P值均 &lt; 0.01)，CA199的阳性率在ILD组与肺癌组间的差异无统计学意义(P = 0.364)，SCC的阳性率在三组间的差异无统计学意义(P = 0.265)；CEA、CYPRA21-1、CA199、CA125的水平在ILD组与肺癌组间的差异均无统计学意义(P值均 &gt; 0.05)，ILD组、肺癌组中CEA、CYPRA21-1、CA199、CA125的水平均高于支气管哮喘组(P值 &lt; 0.05)，SCC水平的差异在三者间无统计学意义(P = 0.829)，NSE的水平在三组中由高到低为：肺癌组 &gt; ILD组 &gt; 支气管哮喘组(P值均 &lt; 0.05)；结论：① CEA、NSE、CYPRA21-1、CA199、SCC、CA125在ILD患者中有不同程度的升高，但其升高的临床意义目前尚无统一结论；② 支气管哮喘患者中CEA、NSE、CYPRA21-1、CA199、CA125阳性率及水平明显低于ILD及肺癌组；③ 多种肿瘤标记物的水平及阳性率在ILD与肺部恶性肿瘤间的差异无统计学意义，肿瘤标记物对两者的鉴别作用有限。
    Objective: To reveal the relationship between serum tumor markers (CEA, NSE, CYPRA21-1, CA199, SCC, CA125) and interstitial lung disease, and whether there is any difference in the levels of interstitial lung disease, bronchial asthma, and lung cancer. Methods: A total of 100 patients diagnosed with ILD in the First People’s Hospital of Yunnan Province from May 2015 to December 2020 were collected as the case group, and 51 patients diagnosed with bronchial asthma during the same period were collected as the control group A, the same pathology confirmed for 53 patients with lung cancer, for control group B, the levels of CEA, NSE, CYPRA21-1, CA199, SCC and CA125 in the three groups were measured, and the differences of serum tumor markers in each group were compared. Results: The positive rates of serum CEA, NSE, CYPRA21-1 and CA125 in ILD group and lung cancer group had no significant difference (P &gt; 0.05). The positive rates of CEA, NSE, CYPRA21-1 and CA125 in ILD group and lung cancer group were higher than those in asthma group (P &lt; 0.01). There was no statistically significant difference in the positive rate of CA199 between ILD group and lung cancer group (P = 0.364), and there was no statistically significant difference in the positive rate of SCC among the three groups (P = 0.265). The levels of CEA, CYPRA21-1, CA199 and CA125 were not significantly different between ILD group and lung cancer group (P &gt; 0.05). The levels of CEA, CYPRA21-1, CA199 and CA125 in ILD group and lung cancer group were higher than those in asthma group (P &lt; 0.05), but there was no statistical significance in SCC level among the three groups (P = 0.829). NSE level in the three groups from high to low is: lung cancer group &gt; ILD group &gt; Bronchial asthma group (all P &lt; 0.05). Conclusion: ① CEA, NSE, CYPRA21-1, CA199, SCC and CA125 are increased in ILD patients to varying degrees, but there is no unified conclusion on the clinical significance of these increases. ② The positive rates and levels of CEA, NSE, CYPRA21-1, CA199 and CA125 in bronchial asthma patients were significantly lower than those in ILD and lung cancer group. ③ There was no statistical significance in the level and positive rate of various tumor markers between ILD and lung malignant tumors, and the role of tumor markers in the differentiation between ILD and lung malignant tumors was limited. 
  
 
</p></abstract><kwd-group><kwd>间质性肺疾病，支气管哮喘，肺癌，血清肿瘤标记物, Interstitial Lung Disease</kwd><kwd> Bronchial Asthma</kwd><kwd> Lung Cancer</kwd><kwd> Serum Tumor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：揭示血清肿瘤标记物(CEA、NSE、CYPRA21-1、CA199、SCC、CA125)与间质性肺疾病之间的关系，肿瘤标记物阳性率及水平在间质性肺疾病(Interstitial pulmonary disease, ILD)、支气管哮喘、肺癌中有无差异；方法：收集2015年5月至2020年12月于云南省第一人民医院确诊为ILD的患者100例，收集同期诊断为支气管哮喘的患者51例，为对照A组，同期病理证实为肺癌的患者53例，为对照B组，测定三组患者血清中CEA、NSE、CYPRA21-1、CA199、SCC、CA125的水平，比较三组中不同血清肿瘤标记物的差异。结果：ILD组血清CEA、NSE、CYPRA21-1、CA125的阳性率与肺癌组无明显差异(P值均 &gt; 0.05)，ILD组、肺癌组中CEA、NSE、CYPRA21-1、CA125的阳性率均高于支气管哮喘组(P值均 &lt; 0.01)，CA199的阳性率在ILD组与肺癌组间的差异无统计学意义(P = 0.364)，SCC的阳性率在三组间的差异无统计学意义(P = 0.265)；CEA、CYPRA21-1、CA199、CA125的水平在ILD组与肺癌组间的差异均无统计学意义(P值均 &gt; 0.05)，ILD组、肺癌组中CEA、CYPRA21-1、CA199、CA125的水平均高于支气管哮喘组(P值 &lt; 0.05)，SCC水平的差异在三者间无统计学意义(P = 0.829)，NSE的水平在三组中由高到低为：肺癌组 &gt; ILD组 &gt; 支气管哮喘组(P值均 &lt; 0.05)；结论：① CEA、NSE、CYPRA21-1、CA199、SCC、CA125在ILD患者中有不同程度的升高，但其升高的临床意义目前尚无统一结论；② 支气管哮喘患者中CEA、NSE、CYPRA21-1、CA199、CA125阳性率及水平明显低于ILD及肺癌组；③ 多种肿瘤标记物的水平及阳性率在ILD与肺部恶性肿瘤间的差异无统计学意义，肿瘤标记物对两者的鉴别作用有限。</p></sec><sec id="s2"><title>关键词</title><p>间质性肺疾病，支气管哮喘，肺癌，血清肿瘤标记物</p></sec><sec id="s3"><title>Study on the Difference of Tumor Markers in Interstitial Pulmonary Disease, Lung Cancer and Bronchial Asthma</title><p>Xingqiu Duan, Kun Tian, Yunhui Zhang<sup>*</sup></p><p>Clinical Medical College of Dali University, Dali Yunnan</p><p><img src="//html.hanspub.org/file/62-1572163x5_hanspub.png" /></p><p>Received: Mar. 22<sup>nd</sup>, 2021; accepted: Apr. 19<sup>th</sup>, 2021; published: Apr. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/62-1572163x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To reveal the relationship between serum tumor markers (CEA, NSE, CYPRA21-1, CA199, SCC, CA125) and interstitial lung disease, and whether there is any difference in the levels of interstitial lung disease, bronchial asthma, and lung cancer. Methods: A total of 100 patients diagnosed with ILD in the First People’s Hospital of Yunnan Province from May 2015 to December 2020 were collected as the case group, and 51 patients diagnosed with bronchial asthma during the same period were collected as the control group A, the same pathology confirmed for 53 patients with lung cancer, for control group B, the levels of CEA, NSE, CYPRA21-1, CA199, SCC and CA125 in the three groups were measured, and the differences of serum tumor markers in each group were compared. Results: The positive rates of serum CEA, NSE, CYPRA21-1 and CA125 in ILD group and lung cancer group had no significant difference (P &gt; 0.05). The positive rates of CEA, NSE, CYPRA21-1 and CA125 in ILD group and lung cancer group were higher than those in asthma group (P &lt; 0.01). There was no statistically significant difference in the positive rate of CA199 between ILD group and lung cancer group (P = 0.364), and there was no statistically significant difference in the positive rate of SCC among the three groups (P = 0.265). The levels of CEA, CYPRA21-1, CA199 and CA125 were not significantly different between ILD group and lung cancer group (P &gt; 0.05). The levels of CEA, CYPRA21-1, CA199 and CA125 in ILD group and lung cancer group were higher than those in asthma group (P &lt; 0.05), but there was no statistical significance in SCC level among the three groups (P = 0.829). NSE level in the three groups from high to low is: lung cancer group &gt; ILD group &gt; Bronchial asthma group (all P &lt; 0.05). Conclusion: ① CEA, NSE, CYPRA21-1, CA199, SCC and CA125 are increased in ILD patients to varying degrees, but there is no unified conclusion on the clinical significance of these increases. ② The positive rates and levels of CEA, NSE, CYPRA21-1, CA199 and CA125 in bronchial asthma patients were significantly lower than those in ILD and lung cancer group. ③ There was no statistical significance in the level and positive rate of various tumor markers between ILD and lung malignant tumors, and the role of tumor markers in the differentiation between ILD and lung malignant tumors was limited.</p><p>Keywords:Interstitial Lung Disease, Bronchial Asthma, Lung Cancer, Serum Tumor</p><disp-formula id="hanspub.41874-formula46"><graphic xlink:href="//html.hanspub.org/file/62-1572163x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/62-1572163x8_hanspub.png" /> <img src="//html.hanspub.org/file/62-1572163x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>ILD亦称为弥漫性实质性肺疾病(diffuse parenchymal lung disease, DPLD)，是一组主要累及肺间质及肺泡腔，导致肺泡–毛细血管功能单位丧失的弥漫性肺疾病，间质性肺疾病包括200多种急性及慢性肺部疾病 [<xref ref-type="bibr" rid="hanspub.41874-ref1">1</xref>]，严重威胁人类健康，其治疗周期长，费用昂贵，对患者身体及心理都造成极大负担，是目前呼吸系统疾病治疗的难点 [<xref ref-type="bibr" rid="hanspub.41874-ref2">2</xref>]。肿瘤标记物是一类在肿瘤发生或存在过程中由肿瘤细胞分泌或是由肿瘤引起机体分泌的一类血清标志物，其存在对肿瘤的诊断及病情活动、预后有重要作用，相关研究发现，CEA、SCCA、CYFRA21-1、NSE等肿瘤标记物联合检测可能对肺癌的诊断有效 [<xref ref-type="bibr" rid="hanspub.41874-ref3">3</xref>]，有研究对ILD患者血清肿瘤标记物进行检测，发现部分肿瘤标记物有不同程度的升高 [<xref ref-type="bibr" rid="hanspub.41874-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41874-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41874-ref6">6</xref>]，但其升高的程度如何？与肺癌患者相比其水平有无不同？目前研究较少。另外，临床上，间质性肺疾病可继发肺癌，肺癌也可继发间质性肺疾病，间质性肺疾病与肿瘤标志物的关系目前尚无明确定论，临床上抗肿瘤药物尼达尼布用于ILD的治疗，这似乎暗示着ILD与肿瘤标记物间存在着某些联系 [<xref ref-type="bibr" rid="hanspub.41874-ref7">7</xref>] - [<xref ref-type="bibr" rid="hanspub.41874-ref12">12</xref>]。据此，此次研究主要观察ILD患者血清肿瘤标记物的水平及其意义，分析ILD、肺癌、支气管哮喘三者之间血清肿瘤标记物水平及阳性率的差异，为临床工作提供参考。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><sec id="s6_1_1"><title>2.1.1. 研究对象</title><p>收集2015年5月至2020年12月于云南省第一人民医院确诊为间质性肺疾病的患者100例。</p><p>纳入标准为：依据2008年英国胸科协会修订的ILD指南诊断标准 [<xref ref-type="bibr" rid="hanspub.41874-ref13">13</xref>]；排除标准：合并支气管哮喘、慢性阻塞性肺疾病、肺癌及其他系统恶性肿瘤，合并严重的肺实质性病变。</p><p>收集同时期确诊为支气管哮喘的患者51例作为对照A组，同期病理证实为肺癌的患者53例作为对照B组。所有纳入病例均无心、肝、肾、胃肠等脏器肿瘤的证据，除肺癌组患者外，其他各组患者均无肺部肿瘤的证据。</p><p>收集患者的基本信息及血清肿瘤标记物：癌胚抗原(carcinoembryonic antigen, CEA)、神经原特异性烯醇化酶(Neuron-specific enolase, NSE)、细胞角蛋白19片段抗原(Cytokeratin 19 fragment antigen 21-1, CYPRA21-1)、癌抗原19-9(Carbohydrate antigen 19-9, CA199)、鳞状细胞癌抗原(Squamous cell carcinoma antigen, SCC)、癌抗原125(Carbohydrate antigen 125, CA125)。</p></sec><sec id="s6_1_2"><title>2.1.2. 试剂</title><p>试剂盒：癌胚抗原试剂盒、神经原特异性烯醇化酶试剂盒、细胞角蛋白19片段抗原试剂盒、癌抗原125试剂盒、鳞状细胞癌抗原试剂盒、癌抗原199试剂盒。均购自上海雅培贸易有限公司。</p></sec></sec><sec id="s6_2"><title>2.2. 研究方法</title><sec id="s6_2_1"><title>2.2.1. 标本处理</title><p>抽取患者入院当天空腹静脉血5 ml，37℃水浴30 min，分离血清后，NSE、CYPRA21-1用电化学发光法进行测定，CEA、CA199、SCC、CA125用化学发光法进行测定。</p></sec><sec id="s6_2_2"><title>2.2.2. 判定方法</title><p>各指标正常范围为：CEA 0.0~5.0 ng/ml、NSE 0.0~15.2 ng/ml、CYPRA21-1 0.0~3.3 ng/ml、CA199 0~37 u/ml、SCC 0.0~1.5 ng/ml、CA125 0.0~35 u/ml，超出正常范围为阳性，在正常范围内为阴性。</p></sec><sec id="s6_2_3"><title>2.2.3. 结果分析</title><p>分析病例组、对照A组、对照B组间血清中CEA、NSE、CYPRA21-1、CA199、SCC、CA125阳性率的差异，分析三组间各血清肿瘤标物水平的差异。</p></sec></sec><sec id="s6_3"><title>2.3. 统计学处理</title><p>使用SPSS 20.0进行统计处理，满足正态分布的数据使用均数&#177;标准差表示，使用参数检验，不满足正态分布的数据使用四分位数间距表示，使用非参数检验，P &lt; 0.05有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 基本情况</title><p>ILD组共有100例，女性占64%，年龄为59.42 &#177; 11.03岁，吸烟者占33%；对照A组51例，女性占70.59%，年龄为51.20 &#177; 12.82岁，吸烟者占21.57%；对照B组53例，女性占22.64%，年龄为58.74 &#177; 10.51岁，吸烟者占69.81%；三组间年龄差异无统计学意义(P &gt; 0.05)。</p></sec><sec id="s7_2"><title>3.2. 各组肿瘤标记物阳性率情况(阳性例数/总例数)</title><p>6种血清肿瘤标记物的在100名ILD患者中存在不同程度的异常，阳性率最高者达71.0%，6种肿瘤标记物在53名对照B组中，有17%~56.6%的异常，对照A组肿瘤标记物阳性率最低，为0.0%~23.5%，CA199在51例对照A组中无异常者，详见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The positive rate of serum tumor markers in the three group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >CEA</th><th align="center" valign="middle" >NSE</th><th align="center" valign="middle" >CYPRA21-1</th><th align="center" valign="middle" >CA199</th><th align="center" valign="middle" >SCC</th><th align="center" valign="middle" >CA125</th></tr></thead><tr><td align="center" valign="middle" >ILD(%)</td><td align="center" valign="middle" >32.0 (32/100)</td><td align="center" valign="middle" >45.0 (45/100)</td><td align="center" valign="middle" >71.0 (71/100)</td><td align="center" valign="middle" >20.0 (20/100)</td><td align="center" valign="middle" >17.0 (17/100)</td><td align="center" valign="middle" >35.0 (35/100)</td></tr><tr><td align="center" valign="middle" >对照A组<sup>#</sup>(%)</td><td align="center" valign="middle" >9.8 (5/51)</td><td align="center" valign="middle" >23.5 (12/51)</td><td align="center" valign="middle" >21.6 (11/51)</td><td align="center" valign="middle" >0.0 (0/51)</td><td align="center" valign="middle" >27.5 (14/51)</td><td align="center" valign="middle" >11.76 (6/51)</td></tr><tr><td align="center" valign="middle" >对照B组(%)</td><td align="center" valign="middle" >37.7 (20/53)</td><td align="center" valign="middle" >50.9 (27/53)</td><td align="center" valign="middle" >56.6 (30/53)</td><td align="center" valign="middle" >26.4 (14/53)</td><td align="center" valign="middle" >17.0 (9/53)</td><td align="center" valign="middle" >45.3 (24/53)</td></tr></tbody></table></table-wrap><p>表1. 三组血清肿瘤标记物阳性率情况</p><p><sup>#</sup>对照A组为哮喘组，对照B组为肺癌组。</p><p>将ILD组、对照A组、对照B组血清肿瘤标记物阳性率进行比较，ILD组血清中CEA、NSE、CYPRA21-1、CA125的阳性率与对照B组无明显差异(P值均 &gt; 0.05)，ILD组、对照B组血清中CEA、NSE、CYPRA21-1、CA125的阳性率均高于对照A组，差异具有统计学意义(P值均 &lt; 0.01)。CA199阳性率在ILD组与对照B组间的差异无统计学意义(P = 0.364)，SCC的阳性率在三组间无明显差异(P = 0.265)。</p></sec><sec id="s7_3"><title>3.3. 三组血清肿瘤标记物水平比较</title><p>ILD组与对照B组中CEA、CYPRA21-1、CA199、CA125的水平的差异无明显统计学意义(P &gt; 0.05)，但两组血清中CEA、CYPRA21-1、CA199、CA125的水平均高于对照A组(P值 &lt; 0.05)；SCC的水平在三者间无明显差异(P = 0.829)；NSE的水平在三组中由高到低为：对照B组 &gt; ILD组 &gt; 对照A组(P值均&lt; 0.05)。各组肿瘤标记物的水平详见表2、表3。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Serum levels of CEA, NSE and CYPRA21-1 in the three groups (median, interquartile interval</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >ILD组<sup>#</sup></th><th align="center" valign="middle" >对照A组</th><th align="center" valign="middle" >对照B组</th><th align="center" valign="middle" >P1<sup>*</sup></th><th align="center" valign="middle" >P2</th><th align="center" valign="middle" >P3</th></tr></thead><tr><td align="center" valign="middle" >CEA (ng/ml)</td><td align="center" valign="middle" >3.21 (1.96, 6.22)</td><td align="center" valign="middle" >2.37 (1.78, 3.30)</td><td align="center" valign="middle" >3.77 (1.97, 9.74)</td><td align="center" valign="middle" >0.91</td><td align="center" valign="middle" >0.043</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >NSE (ng/ml)</td><td align="center" valign="middle" >14.82 (12.10, 17.58)</td><td align="center" valign="middle" >12.24 (10.14, 14.92)</td><td align="center" valign="middle" >15.00 (12.87, 26.81)</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >CYPRA21-1 (ng/ml)</td><td align="center" valign="middle" >4.15 (2.90, 5.56)</td><td align="center" valign="middle" >2.07 (1.63, 3.18)</td><td align="center" valign="middle" >3.67 (2.15, 6.79)</td><td align="center" valign="middle" >0.82</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表2. 三组患者血清中CEA、NSE、CYPRA21-1的水平情况(中位数，四分位数间距)</p><p><sup>#</sup>ILD组为病例组，对照A组为哮喘组，对照B组为肺癌组，<sup>*</sup>P1为ILD组与对照B组比较，P2为ILD组与对照A组比较，P3为对照B组与对照A组比较。</p><table-wrap-group id="3"><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Serum levels of CA199, SCC and CA125 in the three groups (median, interquartile interval</title></caption><table-wrap id="3_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >ILD组<sup>#</sup></th><th align="center" valign="middle" >对照A组</th><th align="center" valign="middle" >对照B组</th><th align="center" valign="middle" >P1<sup>*</sup></th><th align="center" valign="middle" >P2</th><th align="center" valign="middle" >P3</th></tr></thead><tr><td align="center" valign="middle" >CA199 (u/ml)</td><td align="center" valign="middle" >7.89 (2.67, 23.71)</td><td align="center" valign="middle" >5.58 (2.79, 10.55)</td><td align="center" valign="middle" >12.06 (4.58, 49.00)</td><td align="center" valign="middle" >0.27</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >0.006</td></tr></tbody></table></table-wrap><table-wrap id="3_2"><table><tbody><thead><tr><th align="center" valign="middle" >SCC (ng/ml)</th><th align="center" valign="middle" >0.80 (0.53, 1.28)</th><th align="center" valign="middle" >0.90 (0.60, 1.60)</th><th align="center" valign="middle" >0.90 (0.55, 1.30)</th><th align="center" valign="middle" >&gt;0.05</th><th align="center" valign="middle" >&gt;0.05</th><th align="center" valign="middle" >&gt;0.05</th></tr></thead><tr><td align="center" valign="middle" >CA125 (u/ml)</td><td align="center" valign="middle" >25.00 (15.00, 46.00)</td><td align="center" valign="middle" >15.00 (10.90, 22.00)</td><td align="center" valign="middle" >30.00 (15.00, 138.00)</td><td align="center" valign="middle" >0.56</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >&lt;0.01</td></tr></tbody></table></table-wrap></table-wrap-group><p>表3. 三组患者血清中CA199、SCC、CA125的水平情况(中位数，四分位数间距)</p><p><sup>#</sup>ILD组为病例组，对照A组为哮喘组，对照B组为肺癌组，<sup>*</sup>P1为ILD组与对照B组比较，P2为ILD组与对照A组比较，P3为对照B组与对照A组比较</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>此次100名ILD患者中，女性占大多数，年龄为59.42 &#177; 11.03岁，吸烟者占入组患者的三分之一，血清中肿瘤标记物存在不同程度的异常，阳性率最高者达71%，肺癌及支气管哮喘患者中，肿瘤标记物也有不同程度的升高，相关研究表明，吸烟可能使血清中部分炎性标记物发生改变，戒烟后可使这些炎性标记物出现不同程度的下降，吸烟与某些特定的ILD存在着密切的联系 [<xref ref-type="bibr" rid="hanspub.41874-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.41874-ref15">15</xref>]，但吸烟是否与肿瘤标记物的变化有关，有待继续研究。ILD的发病及预后可能与性别有一定的关系，相关研究表明，男性合并OSA可能与疾病的预后较差有关 [<xref ref-type="bibr" rid="hanspub.41874-ref16">16</xref>]。</p><p>相关研究证实，肺癌患者血清中CYFRA21-1、SCC、NSE、CEA的水平明显高于正常参考范围，且高于肺部良性疾病，据此有助于肺癌的诊断及转移的评估 [<xref ref-type="bibr" rid="hanspub.41874-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.41874-ref18">18</xref>]，CYFRA 21-1和ProGRP在与肺癌密切相关，但在肺部良性疾病中无特异性 [<xref ref-type="bibr" rid="hanspub.41874-ref19">19</xref>]，但CYFRA21-1可能对CTD-ILD的发现起到预测及协助诊断的作用 [<xref ref-type="bibr" rid="hanspub.41874-ref20">20</xref>]，此次研究发现，肺癌组中CEA、CYPRA21-1的阳性率及水平均高于支气管哮喘组，与前述学者的研究相同，但在间质性肺疾病组及肺癌组中CEA、CYPRA21-1的水平及阳性率的差异无明显统计学意义(P值均 &gt; 0.05)，SCC的阳性率及水平在三组中的差异无统计学意义(P值均&gt;0.05)，可见血清中肿瘤标记物的升高，并不仅仅只存在恶性肿瘤中。在一项CTD-ILD的研究中发现，与单纯RA组相比，合并ILD的患者血清中CA125、CA153、CA199的水平有所升高，三者可能是结缔组织病出现肺部病变的预测因子 [<xref ref-type="bibr" rid="hanspub.41874-ref21">21</xref>]，相同研究指出，在RA患者中年龄较大及CA125水平升高可能与肺部病变的发生有关 [<xref ref-type="bibr" rid="hanspub.41874-ref22">22</xref>]，部分学者指出，CEA及CA125可能是ILD患者罹患肺癌的标志物 [<xref ref-type="bibr" rid="hanspub.41874-ref23">23</xref>]，此次研究中ILD及肺癌患者血清中CA125及CA199的水平亦有所升高，但在两疾病中差异无统计学意义(P值均&gt;0.05)，确切的意义有待进一步研究。</p><p>CA199为胃肠道相关的肿瘤标记物，在部分呼吸系统疾病中其水平也会出现一定程度的变化，相关研究指出在ILD患者中，CA199升高者比正常者生存率低 [<xref ref-type="bibr" rid="hanspub.41874-ref24">24</xref>]，Mukae [<xref ref-type="bibr" rid="hanspub.41874-ref25">25</xref>] 等学者对两例间质性肺炎患者的观察发现，其血清中CA199的水平明显升高，且随着疾病的发展而变化，较高水平与预后不良有关。此次研究发现，100名ILD患者CA199阳性率为20%，水平为7.89 (2.67, 23.71) u/ml，其阳性率及水平与肺癌组无明显差异(P值均&gt;0.05)，两组中CA199的阳性率及水平均高于支气管哮喘组，遗憾的是此次研究并未对ILD患者病情及肿瘤标记物的变化进行追踪。一项回顾性分析显示，肺癌患者血清中CEA、CYFRA21-1、NSE、CA125的水平明显高于肺部良性疾病者，四者联合对肺癌的诊断具有一定价值 [<xref ref-type="bibr" rid="hanspub.41874-ref26">26</xref>]，此次研究发现ILD患者血清中NSE阳性率为45%，水平为14.82 (12.10, 17.58) ng/ml，低于肺癌组，高于支气管哮喘组，临床上关于NSE与ILD的研究较少，目前尚未明确其升高对ILD患者的临床意义。</p><p>此次研究表明，CEA、NSE、CYPRA21-1、CA199、SCC、CA125在ILD患者中有不同程度的升高，但其升高的临床意义目前尚无统一结论；支气管哮喘患者中CEA、NSE、CYPRA21-1、CA199、CA125阳性率及水平明显低于ILD及肺癌组；多种肿瘤标记物的水平及阳性率在ILD与肺部恶性肿瘤间的差异无统计学意义，肿瘤标记物对两者的鉴别作用有限，但由于此次研究样本量较少，研究结果可能存在偏倚，更多有价值的研究有待进一步开展。</p></sec><sec id="s9"><title>基金项目</title><p>国家级大学生创新训练项目，项目编号：201910679012，项目类别：重点项目。</p></sec><sec id="s10"><title>文章引用</title><p>段兴秋,田 琨,张云辉. 间质性肺疾病与血清肿瘤标记物的关系Study on the Difference of Tumor Markers in Interstitial Pulmonary Disease, Lung Cancer and Bronchial Asthma[J]. 临床医学进展, 2021, 11(04): 1240-1246. https://doi.org/10.12677/ACM.2021.114269</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41874-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">葛均波, 徐永健. 内科学[M]. 第8版. 北京: 人民卫生出版社, 2019: 87-98.</mixed-citation></ref><ref id="hanspub.41874-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">刘庆伟, 邵美华, 赵亚玲, 尹霄朦, 姜园园, 朱秀丽. 间质性肺疾病患者生活质量现状及影响因素研究[J]. 中国慢性病预防与控制, 2021, 29(3): 201-205.</mixed-citation></ref><ref id="hanspub.41874-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">方高洁, 胡娟. 肿瘤标记物CEA、SCCA、CYFRA21-1联合NSE检测对肺癌的诊断价值分析[J]. 实用癌症杂志, 2019, 34(7): 1161-1163+1175.</mixed-citation></ref><ref id="hanspub.41874-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">杨嫄, 郝景程, 陈媛, 刘毅, 谢其冰, 尹耕. 肿瘤相关标志物在皮肌炎合并间质性肺病患者中的意义[J]. 四川大学学报(医学版), 2018, 49(2):195-199.</mixed-citation></ref><ref id="hanspub.41874-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sargin, G., Köse, R. and Şentürk, T. (2018) Tumor-Associated Antigens in Rheumatoid Arthritis Interstitial Lung Disease or Malignancy? Archives of Rheumatology, 33, 431-437. &lt;br&gt;https://doi.org/10.5606/ArchRheumatol.2018.6691</mixed-citation></ref><ref id="hanspub.41874-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">林蕊艳, 张新, 李晓辉, 胥振扬. 间质性肺疾病血清肿瘤标记物升高的临床意义[J]. 中国临床药理学杂志, 2011, 27(8): 623-625.</mixed-citation></ref><ref id="hanspub.41874-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">朱杰. 肺特发性间质性肺炎与结缔组织病相关性间质性肺疾病的比较分析[J]. 基层医学论坛, 2019, 23(13): 1840-1841.</mixed-citation></ref><ref id="hanspub.41874-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">杨红娇, 董昭兴, 王颖. 特发性肺纤维化生物标志物的研究进展[J]. 中国呼吸与危重监护杂志, 2019, 18(2): 204-208.</mixed-citation></ref><ref id="hanspub.41874-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">魏文静, 任钰荣, 发如克·帕尔哈提, 李风森. 间质性肺疾病与肿瘤标志物相关性的研究进展[J]. 新疆中医药, 2018, 36(6): 86-89.</mixed-citation></ref><ref id="hanspub.41874-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Calabrese, F., Lunardi, F., Giacometti, C., Marulli. G., Gnoato, M., Pontisso, P., et al. (2008) Overexpession of Squamous Cell Carcinoma Antigen in Idiopathic Pulmonary Fibrosis: Clinicopathological Correlation. Thorax, 63, 795-802.  
&lt;br&gt;https://doi.org/10.1136/thx.2007.088583</mixed-citation></ref><ref id="hanspub.41874-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Molina, R., Auge, J.M., Escudero, J.M., Marrades, R., Viñolas, N., Carcereny, E., et al. (2008) Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor Biology, 29, 371-380. &lt;br&gt;https://doi.org/10.1159/000181180</mixed-citation></ref><ref id="hanspub.41874-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Totani, Y., Saito, Y., Miyachi, H., Shimizu, H., Hoshino, T., Hayashi, M., et al. (2005) Clinical Characterization of CA19-9 in Patients with Interstitial Pneumonia Showing Pathological Nonspecific Interstitial Pneumonia Patter. Nihon Kokyuki Gakkai Zasshi, 43, 77-83.</mixed-citation></ref><ref id="hanspub.41874-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wells, A.U. and Hirani, N. (2008) Interstitial Lung Disease Guideline. Thorax, 63, v1-v58.  
&lt;br&gt;https://doi.org/10.1136/thx.2008.101691</mixed-citation></ref><ref id="hanspub.41874-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Shiels, M.S., Katki, H.A., Freedman, N.D., Purdue, M.P., Wentzensen, N., Trabert, B., et al. (2014) Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers. Journal of the National Cancer Institute, 106, dju294.  
&lt;br&gt;https://doi.org/10.1093/jnci/dju294</mixed-citation></ref><ref id="hanspub.41874-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Crotty Alexander, L.E., Shin, S. and Hwang, J.H. (2015) Inflammatory Diseases of the Lung Induced by Conventional Cigarette Smoke: A Review. Chest, 148, 1307-1322. &lt;br&gt;https://doi.org/10.1378/chest.15-0409</mixed-citation></ref><ref id="hanspub.41874-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wong, A.W., Lee, T.Y., Johannson, K.A., Assayag, D., Morisset, J., Fell, C.D., et al. (2020) A Cluster-Based Analysis Evaluating the Impact of Comorbidities in Fibrotic Interstitial Lung Disease. Respiratory Research, 21, Article No. 322.  
&lt;br&gt;https://doi.org/10.1186/s12931-020-1296-3</mixed-citation></ref><ref id="hanspub.41874-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">刘志华, 卢旭妹, 容亓. 血清标志物CYFRA21-1、SCC、NSE、CEA及ProGRP联合检测在非小细胞性肺癌中的诊断价值[J]. 河北医药, 2019, 41(10): 1464-1468.</mixed-citation></ref><ref id="hanspub.41874-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Chu, Y., Li, J., Zeng, F., Wu, M., Wang, T., et al. (2020) Development of a Prediction Model with Serum Tumor Markers to Assess Tumor Metastasis in Lung Cancer. Cancer Medicine, 9, 5436-5445.  
&lt;br&gt;https://doi.org/10.1002/cam4.3184</mixed-citation></ref><ref id="hanspub.41874-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Matsubara, Y., Iwashita, T., Ishimatsu, Y., Shikuwa, C., Kadota, J. and Kohno, S. (2000) Evaluation of CYFRA 21-1 and ProGRP in Serum and Bronchoalveolar Lavage Fluid of Patients with Benign Lung Disease. Nihon Kokyuki Gakkai Zasshi, 38, 659-664.</mixed-citation></ref><ref id="hanspub.41874-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Suzuki, A., Masuda, T., Koito, N., Suzuki, T., Mita, S., Matsuoka, Y., et al. (1996) Studies of Serum Markers in Patients with Interstitial Pneumonia/Pulmonary Fibrosis Complicated with Collagen Diseases: Clinical Evaluation of CYFRA21-1. Ryumachi, 36, 837-843.</mixed-citation></ref><ref id="hanspub.41874-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, M., Lou, A., Zhang, H., et al. (2021) Serum KL-6, CA19-9, CA125 and CEA Are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population. Rheumatology and Therapy, 8, 517-527. &lt;br&gt;https://doi.org/10.1007/s40744-021-00288-x</mixed-citation></ref><ref id="hanspub.41874-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wang, T., Zheng, X.J., Ji, Y.L., Liang, Z.-A. and Liang, B.-M. (2016) Tumour Markers in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Clinical and Experimental Rheumatology, 34, 587-591.</mixed-citation></ref><ref id="hanspub.41874-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Dai, H., Liu, J., Liang, L., Ban, C., Jiang, J., Liu, Y., et al. (2014) Increased Lung Cancer Risk in Patients with Interstitial Lung Disease and Elevated CEA and CA125 Serum Tumour Markers. Respirology, 19, 707-713.  
&lt;br&gt;https://doi.org/10.1111/resp.12317</mixed-citation></ref><ref id="hanspub.41874-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Kodama, T., Satoh, H., Ishikawa, H. and Ohtsuka, M. (2007) Serum Levels of CA19-9 in Patients with Nonmalignant Respiratory Diseases. Journal of Clinical Laboratory Analysis, 21, 103-106. &lt;br&gt;https://doi.org/10.1002/jcla.20136</mixed-citation></ref><ref id="hanspub.41874-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Mukae, H., Sakito, O., Oda, H., Senju, R., Fukushima, K., Hiratani, K., et al. (1991) Two Cases of Interstitial Pneumonitis with Marked Increase of Tumor-Associated Carbohydrate Antigens in Serum. Nihon Kyobu Shikkan Gakkai Zasshi, 29, 611-617.</mixed-citation></ref><ref id="hanspub.41874-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">龚岚, 罗晓云. CEA、CY211、NSE、Ca125联合诊断肺癌的ROC曲线分析[J]. 中华肺部疾病杂志(电子版), 2020, 13(6): 777-780.</mixed-citation></ref></ref-list></back></article>